









Markets
/
Stocks
/
nasdaq-tars
/

Tarsus Pharmaceuticals Inc

TARS

64.620USD

+2.630+4.24%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.74BMarket Cap

LossP/E TTM



Tarsus Pharmaceuticals Inc

64.620

+2.630+4.24%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Tarsus Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Tarsus Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 88.78.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tarsus Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

32 / 159

Overall Ranking

95 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Tarsus Pharmaceuticals Inc Highlights

StrengthsRisks

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 608.68% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 182.95M.

Undervalued

The company’s latest PE is -32.41, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 46.63M shares, decreasing 15.93% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 21.72K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

88.778

Target Price

+39.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Tarsus Pharmaceuticals Inc is 8.13, ranking 84 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 118.70M, representing a year-over-year increase of 146.68%, while its net profit experienced a year-over-year increase of 46.26%.

Score

Industry at a Glance

Previous score

8.13

Change



Financials

7.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.73

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.64

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Tarsus Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Tarsus Pharmaceuticals Inc is 7.12, ranking 96 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -32.41, which is -89.58% below the recent high of -3.38 and -27.69% above the recent low of -41.38.

Score

Industry at a Glance

Previous score

7.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 32/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Tarsus Pharmaceuticals Inc is 8.80, ranking 7 out of 159 in the Pharmaceuticals industry. The average price target is 88.00, with a high of 100.00 and a low of 51.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

88.778

Target Price

+39.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Tarsus Pharmaceuticals Inc

TARS

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Tarsus Pharmaceuticals Inc is 6.94, ranking 95 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 75.88 and the support level at 57.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.67

Change

0.27

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.702

Sell

RSI(14)

34.898

Neutral

STOCH(KDJ)(9,3,3)

25.280

Neutral

ATR(14)

3.090

High Vlolatility

CCI(14)

-84.498

Neutral

Williams %R

75.720

Sell

TRIX(12,20)

-0.830

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

64.582

Buy

MA10

65.343

Sell

MA20

69.154

Sell

MA50

76.003

Sell

MA100

71.655

Sell

MA200

58.898

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Tarsus Pharmaceuticals Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 109.85%, representing a quarter-over-quarter decrease of 5.16%. The largest institutional shareholder is The Vanguard, holding a total of 2.39M shares, representing 5.63% of shares outstanding, with 6.62% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RTW Investments L.P.

3.18M

+2.11%

BlackRock Institutional Trust Company, N.A.

3.09M

-0.82%

Deep Track Capital LP

3.00M

+27.50%

Paradigm BioCapital Advisors LP

2.67M

-10.43%

Tang Capital Management, LLC

2.45M

The Vanguard Group, Inc.

Star Investors

2.26M

-1.10%

Jennison Associates LLC

2.60M

+5.53%

Morgan Stanley & Co. LLC

1.78M

-2.50%

Janus Henderson Investors

1.44M

-20.36%

Frazier Life Sciences Management, L.P.

1.17M

-16.46%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tarsus Pharmaceuticals Inc is 7.23, ranking 40 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.